Table 1

Clinical characteristics of patient A

Age/ sexTime from diagnosis to HSCT, moTherapies prior to HSCTHSCT conditioning regimenStem cell dose, cells/kg body wtStem cell sourceTime from HSCT to complete response, mo*Time from HSCT to molecular response, mo
48/F 108 Lenalidomide, bortezomib, dexamethasone High-dose melphalan 6.85 × 106 PBSCs 2.6 24 
Age/ sexTime from diagnosis to HSCT, moTherapies prior to HSCTHSCT conditioning regimenStem cell dose, cells/kg body wtStem cell sourceTime from HSCT to complete response, mo*Time from HSCT to molecular response, mo
48/F 108 Lenalidomide, bortezomib, dexamethasone High-dose melphalan 6.85 × 106 PBSCs 2.6 24 
*

Defined as negative immunofixation and monoclonal protein of 0 g/dL.

PBSCs indicates peripheral blood stem cells.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal